TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioHarvest Sciences ( (BHST) ) has shared an announcement.
BioHarvest Sciences announced its participation in the Craig-Hallum 16th Annual Alpha Select Conference, where CEO Ilan Sobel will engage with institutional investors. The company is experiencing strong momentum in its consumer and CDMO divisions, driven by the success of its VINIA® capsule business and the introduction of new products like VINIA® Daily Chews 2X Formula and VINIA® Blood Flow Hydration Solution. Additionally, BioHarvest is advancing its CDMO platform with breakthroughs in plant-based exosome production and a new contract for developing a saffron compound. Supported by a recent $19.9 million equity offering, the company is focused on achieving adjusted EBITDA breakeven and delivering sustainable growth and long-term value for shareholders.
The most recent analyst rating on (BHST) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
BioHarvest Sciences faces significant financial challenges, with high leverage and negative equity impacting its financial stability. Despite this, the company shows potential for growth through strategic initiatives and product launches, as highlighted in the earnings call. Technical indicators suggest bearish momentum, and the valuation remains unattractive due to ongoing losses.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a leader in the Botanical Synthesis industry, utilizing its patented technology to grow plant-based compounds without cultivating the actual plants. The company operates in two main business areas: as a contract development and production organization (CDMO) for clients seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements.
Average Trading Volume: 76,466
Technical Sentiment Signal: Buy
Current Market Cap: $143.2M
For an in-depth examination of BHST stock, go to TipRanks’ Overview page.